Shares of Abbott Laboratories (ABT) lost ~7% to reach a 52-week low on Thursday after the MedTech giant lowered its full-year earnings outlook, indicating an impact from its recent acquisition of ...
Exact Sciences deal adds $3 billion in incremental sales in 2026, CEO Ford says Nutrition sales fell 6%; diabetes and heart devices face competition, analysts note Middle East conflict causes minor ...
ABBOTT PARK, Ill., March 23, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer ...
MADISON, Wis. -- Abbott expects to close its acquisition of Exact Sciences on Monday, the healthcare giant said. Madison-based Exact Sciences is known for its cancer detection technology such as ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The deal brings Exact Sciences ...
Abbott announced plans to buy Exact in November, in the largest medtech deal announced last year. Exact makes the Cologuard test, a noninvasive option to screen for colorectal cancer. The company also ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...
MADISON, Wis. — Madison-based Exact Sciences, which leads the market with in-home cancer tests Cologuard and Oncotype DX, has been acquired by Abbott for around $21 billion. In the closing of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results